The role of chemotherapy and targeted agents in patients with metastatic breast cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Johnston, Stephen R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; ERIBULIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; INIPARIB; IXABEPILONE; LAPATINIB; MELPHALAN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; NERATINIB; OLAPARIB; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CYTOTOXICITY; DIARRHEA; DRUG SAFETY; FEBRILE NEUTROPENIA; FLUID RETENTION; HAIR LOSS; HUMAN; MONOTHERAPY; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 80053223437     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70145-9     Document Type: Article

References (67)

1. IF Tannock, NF Boyd, G DeBoer et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer J Clin Oncol 6 9 1988 Sep 1377 1387 (Pubitemid 19089025)
2. RW Carlson Quality of life issues in the treatment of metastatic breast cancer Oncology (Huntingt) 12 3Suppl4 1998 Mar 27 31
3. AJ Ramirez, KE Towlson, MS Leaning, MA Richards, RD Rubens Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78 l 1 1998 Dec 1488 1494 (Pubitemid 28517546)
4. S Cold, NV Jensen, H Brincker, C Rose The influence of chemotherapy on survival after recurrence in breast cancer -a population based study of patients treated in the 1950s, 1960s and 1970s Eur J Cancer 29A 8 1993 1146 1152 (Pubitemid 23156640)
5. MB Ross, AU Buzdar, TL Smith et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy Cancer 55 2 1985 Jan 15 341 346
6. E Andreopoulou, GN Hortobagyi Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy J Clin Oncol 26 22 2008 Aug 1 3660 3662
7. AU Buzdar, SS Legha, GN Hortobagyi et al. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens Cancer 47 12 1981 Jun 15 2798 2802 (Pubitemid 11066870)
8. U Banerji, A Kuciejewska, S Ashley et al. Factors determining outcome after third line chemotherapy for metastatic breast cancer Breast (Edinburgh, Scotland) 16 4 2007 Aug 359 366 (Pubitemid 47109195)
9. L Pusztai, G Viale, CM Kelly, CA Hudis Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis Oncologist 15 ll 2010 1164 1168
10. GW Sledge, D Neuberg, P Bernardo et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (El 193) J Clin Oncol 21 4 2003 Feb 15 588 592 (Pubitemid 46621890)
11. E Heidemann, H Stoeger, Rea Souchon Is first line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial Ann Oncol 11 13 2002 1717 1729 (Pubitemid 35439451)
12. R Fossati, C Confalonieri, V Torri et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 16 10 1998 3439 3460 (Pubitemid 28481644)
13. F Cardoso, PL Bedard, EP Winer et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy J Nati Cancer Inst 101 17 2009 Sep 2 1174 1181
14. RP A'Hern, IE Smith, SR Ebbs Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens Br J Cancer 4 67 1993 801 805 (Pubitemid 23101563)
15. S Chan, K Friedrichs, D Noel et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 1999 2341 2354 (Pubitemid 29368232)
16. DJ Slamon, B Leyland-Jones, S Shak et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 NEngl JMed 344 11 2001 Mar 15 783 792 (Pubitemid 32222155)
17. ME O'Brien, N Wigler, M Inbar et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin as first-line treatment of metastatic breast cancer Ann Oncol 15 3 2004 440 449 (Pubitemid 38444547)
18. ME Trudeau, MJ Clemons, L Provencher et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines J Clin Oncol 27 35 2009 Dec 10 5906 5910
19. D Ghersi, N Wilcken, J Simes, E Donoghue Taxane containing regimens for metastatic breast cancer Cochrane database of systematic reviews (Online) 3 2003 CD003366
20. AD Seidman, D Berry, C Cirrincione et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 10 2008 Apr 1 1642 1649
21. SE Jones, J Erban, B Overmoyer et al. J Clin Oncol 23 24 2005 5542 5551
22. HJ Burstein, J Manola, J Younger et al. Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 2000 1212 1219 (Pubitemid 30159838)
23. WJ Gradishar, S Tjulandin, N Davidson et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 31 2005 7794 7803 (Pubitemid 46657376)
24. WJ Gradishar, D Krasnojon, S Cheporov et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer JClin Oncol 27 22 2009 3611 3619
25. P Fumoleau, FM Delgado, T Delozier et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy J Clin Oncol 11 7 1993 Jul 1245 1252 (Pubitemid 23199126)
26. S Jones, E Winer, C Vogel et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer J Clin Oncol 13 10 1995 Oct 2567 2574
27. J Bonneterre, H Roche, A Monnier et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure Br J Cancer 87 ll 2002 Nov 18 1210 1215 (Pubitemid 36009124)
28. B Norris, KI Pritchard, K James et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastaticrecurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 JClin Oncol 18 12 2000 Jun 2385 2394 (Pubitemid 30415825)
29. JA Low, SB Wedam, JJ Lee et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer J Clin Oncol 23 12 2005 Apr 20 2726 2734 (Pubitemid 46179462)
30. E Thomas, J Tabernero, M Former et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 23 2007 Aug 10 3399 3406 (Pubitemid 47310875)
31. JA Sparano, E Vrdoljak, O Rixe et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 20 2010 Jul 10 3256 3263
32. LT Vahdat, B Pruitt, CJ Fabian et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 27 18 2009 Jun 20 2954 2961
33. J Cortes, J O'Shaughnessy, D Loesch et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE); a phase 3 open-label randomised study Lancet 377 2011 914 923
34. JL Blum, SE Jones, AU Buzdar et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer JClin Oncol 17 2 1999 Feb 485 493 (Pubitemid 29075232)
35. JL Blum, PM Dieras y Lo Russo et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 7 2001 Oct 1 1759 1768 (Pubitemid 32952493)
36. P Fumoleau, R Largillier, C Clippe et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 4 2004 Mar 536 542 (Pubitemid 38220770)
37. J O'Shaughnessy Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 12 2002 2812 2823 (Pubitemid 34651510)
38. JA Sparano, E Vrdoljak, O Rixe et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and ataxane J Clin Oncol 28 20 2010 3256 3263
39. KS Albain, SM Nag, G Calderillo-Ruiz et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 24 2008 3950 3957
40. A Urruticoechea, CD Archer, LA Assersohn et al. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer Br J Cancer 92 3 2005 Feb 14 475 479 (Pubitemid 40395527)
41. H Kennecke, R Yerushalmi, R Woods et al. Metastatic behaviour of breast cancer subtypes J Clin Oncol 28 2010 3271 3277
42. MA Cobleigh, CL Vogel, D Tripathy et al. Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 9 1999 2639 2648 (Pubitemid 29415219)
43. J Baselga, D Tripathy, J Mendelsohn et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer Semin Oncol 26 4 Suppl 12 1999 78 83 (Pubitemid 29411436)
44. CL Vogel, MA Cobleigh, D Tripathy et al. First-line Herceptin monotherapy in metastatic breast cancer Oncology 61 Suppl 2 2001 37 42 (Pubitemid 33033423)
45. B Leyland-Jones, K Gelmon, JP Ayoub et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 21 21 2003 3965 3971 (Pubitemid 46606210)
46. M Marty, F Cognetti, D Maraninchi et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 2005 4265 4274 (Pubitemid 46207001)
47. HJ Burstein, A Keshaviah, AD Baron et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study Cancer 110 5 2007 965 972 (Pubitemid 47312860)
48. R Bartsch, C Wenzel, G Altorjai et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer J Clin Oncol 25 25 2007 3853 3858 (Pubitemid 47477260)
49. G von Minckwitz, A du Bois, M Schmidt, N Maass et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study J Clin Oncol 27 12 2009 1999 2006
50. HL Gomez, DC Doval, MA Chavez et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer J Clin Oncol 26 18 2008 2999 3005
51. CE Geyer, J Forster, D Lindquist et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl JMed 355 26 2006 2733 2743 (Pubitemid 46021510)
52. S Johnston, J Pippen, M Lichinitser et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 33 2009 5538 5546
53. NU Lin, V Dieras, D Paul et al. Multicenter phase II study of lapatinib in patients with brain métastases from HER2-positive breast cancer Clin Cancer Res 15 4 2009 1452 1459
54. S Sutherland, S Ashley, D Miles et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain métastases - the UK experience Br J Cancer 102 6 2010 995 1002
55. KL Blackwell, HJ Burstein, AM Storniolo et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 7 2010 1124 1130
56. IE Krop, M Beeram, S Modi et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J Clin Oncol 28 16 2010 2698 2704
57. J Baselga, KA Gelmon, S Verma et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 7 2010 1138 1144
58. R Swaby, K Blackwell, Z Jiang et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study J Clin Oncol 27 15s 2009 abstract 1004.
59. K Miller, M Wang, J Gralow et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2007 Dec 27 2666 2676
60. DW Miles, A Chan, LY Dirix et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 20 2010 Jul 10 3239 3247
61. H Farmer, N McCabe, CJ Lord et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921 (Pubitemid 40559006)
62. N McCabe, NC Turner, CJ Lord et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115 (Pubitemid 44299177)
63. HE Bryant, N Schultz, HD Thomas et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917 (Pubitemid 40559005)
64. PC Fong, DS Boss, TA Yap et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
65. A Tutt, M Robson, JE Garber et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
66. J O'Shaughnessy, C Osborne, JE Pippen et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl JMed 364 2011 205 214
67. J O'Shaughnessy, L Schwartzberg, M Danso et al. A randomised phase III trial of iniparib in combination with gemcitabine and carboplatin in metastatic triple negative breast cancer Proc Am Soc Clin Oncol 2011 (Abstract 1007).